Streptococcal toxic-shock syndrome

Summary

Streptococcal toxic-shock syndrome (MONDO:0020544) is a disease and 1 clinical trial. Top therapeutic interventions include clindamycin. A subtype of toxic shock syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: 1-9 / 1 000 000 (France) [Orphanet-validated]
• Clinical trials: 1

Clinical features

Epidemiology

Prevalence records

4 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.1	France	Validated
Annual incidence	1-9 / 1 000 000	0.2	United States	Validated
Annual incidence	1-9 / 1 000 000	0.33	Sweden	Validated
Annual incidence	1-9 / 1 000 000	0.23	Denmark	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	streptococcal toxic-shock syndrome
Mondo ID	MONDO:0020544
Orphanet	99918
ICD-11	197163558
SNOMED CT	240451000
UMLS	C0343532
MedGen	575664
GARD	0019709
MedDRA	10044251
Is cancer (heuristic)	no

Also known as: streptococcal TSS · Streptococcus caused toxic shock syndrome · Streptococcus toxic shock syndrome

Disease family

This is a subtype of toxic shock syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › commensal bacterial infectious disease › toxic shock syndrome › streptococcal toxic-shock syndrome

Related subtypes (1): staphylococcal toxic-shock syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06126263	Not specified	UNKNOWN	Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CLINDAMYCIN	4	1